TG Therapeutics Inc is a U.S. biopharmaceutical company focused on the development and commercialization of B-cell malignancies and autoimmune disease treatments. The pipeline includes two treatments targeting hematological malignancies and autoimmune diseases: TG-1101 (ublituximab), a glycoengineered monoclonal antibody; and TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 now entering clinical development for autoimmune disorders. The company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies.